68Ga-FAPI-46 PET/CT Scan for Pancreatic Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment 68Ga-FAPI-46 PET/CT Scan for Pancreatic Cancer?
Is the 68Ga-FAPI-46 PET/CT scan safe for humans?
The 68Ga-FAPI PET/CT scan has been used in various studies for imaging tumors and other conditions, and while it shows promise in diagnosing cancers, the safety data specifically for humans is not detailed in the available research. However, it is widely used in clinical settings, suggesting a general acceptance of its safety.36789
How does the 68Ga-FAPI-46 PET/CT scan treatment differ from other treatments for pancreatic cancer?
The 68Ga-FAPI-46 PET/CT scan is unique because it uses a special tracer that targets fibroblast activation protein, which can improve the detection and staging of pancreatic cancer compared to the more commonly used 18F-FDG PET/CT scans. This can lead to better identification of both primary tumors and metastatic lesions, potentially improving treatment planning.123410
What is the purpose of this trial?
This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (CAFs) in patients with pancreatic ductal adenocarcinoma (PDA) that has not spread to other parts of the body (localized). CAFs are a type of connective tissue cell that are found within or near cancerous tissue. Many CAFs express a protein called fibroblast activation protein (FAP) that are not found on healthy cells in large amounts. 68Ga-FAPI-46 is a radioactive chemical compound designed to circulate through the body and attach itself to FAP on PDA cells. A PET/CT scan is then used to detect the location of FAP lesions. PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional (3-D) views of tissues and organs. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination. Giving 68Ga-FAPI-46 PET/CT may help doctors improve upon the diagnosis and management of PDA.
Research Team
Ajit H. Goenka, M.D.
Principal Investigator
Mayo Clinic in Rochester
Eligibility Criteria
This trial is for adults over 18 with localized pancreatic ductal adenocarcinoma (PDA) who haven't started treatment yet. They should be fit enough for surgery after initial therapy and have an ECOG performance status of 0-2, meaning they can care for themselves. Pregnant women, those allergic to ingredients in the scan compound, or patients needing emergency surgery cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Participants receive 68Ga-FAP-46 intravenously and undergo a PET/CT scan at baseline before standard of care therapy
Re-staging Imaging
Participants undergo up to 2 PET/CT scans approximately 8 weeks apart at standard of care re-staging visits
Pre-surgical Imaging
Participants undergo a PET/CT scan within 4 weeks of standard of care surgical resection, if applicable
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Computed Tomography
- Gallium Ga 68 FAPi-46
- Positron Emission Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator